Article: Neose Technologies, Inc. and Monsanto Protein Technologies Sign Research Agreement.

Neose Technologies, Inc. and Monsanto Protein Technologies, a unit of Monsanto Company , today announced that they have entered into a research agreement to investigate the use of Neose's GlycoAdvance(TM) technology to enhance the glycosylation of therapeutic monoclonal antibodies produced in plants.

Today, the majority of therapeutic monoclonal antibodies are produced by mammalian cell culture. The glycosylation patterns of plant-produced monoclonal antibodies differ significantly from monoclonal antibodies produced by mammalian cell culture. Monoclonal antibodies produced in plants have incomplete glycosylation patterns, resulting in the inability to ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!